Shanghai Fosun Signs an Exclusive License Agreement with ReNeuron for its CTX and hRPC Cell Therapy in China

Shots:

• ReNeuron to receive £6.0M ($7.9M) upfront, £6.0M ($7.9M) near-term milestones, £8.0M ($10.5M) regulatory milestones and post-launch profit threshold milestones of 5% on annual profit, leading to total milestones £80.0M ($104.8M) and 12%,14% royalties on net sales of product in China
• Fosun to get exclusive rights to develop and commercialize ReNeuron’s CTX and hRPC cell therapy in China. Additionally, ReNeuron will take care to supply CTX and hRPC cells to Fosun during the transition period
• ReNeuron’s hRPC cell therapy is based on human retinal progenitor cells and is evaluated in P-I/IIa trial in patients with retinitis pigmentosa (RP) in the US with its expected results in H1’19. CTX therapy is currently evaluated in P-I for limb ischaemia

Click here to read full press release/ article | Ref: ReNeuron | Image: WSJ